Johnson & Johnson Financials

Johnson & Johnson

JNJNYSE

Trade with Public

$270.24

2.871.07%

가까이에: Aug 21, 5:00 PM EST

$271.00

0.760.28%

시간외: Aug 21, 7:35 PM EST

배당금: 배당락일은 내일입니다

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 배당금 비교 옵션 주식 보고서

Johnson & Johnson Financials

Johnson & Johnson (JNJ) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Stock Market Today: Dow Jones Futures Gain as Coca-Cola Jumps After Q2 Beat, S&P 500, Nasdaq 100 Decline—Boeing, Johnson & Johnson in Focus (UPDATED)

U.S. stock futures were mixed on Tuesday, as the Dow Jones and S&P 500 indices gained but Nasdaq 100 slipped, following Monday's mixed close.

Rishabh Mishra

Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst

The reasons why RBC Capital Markets maintains its stock rating.

Priya Nigam

Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook

Johnson & Johnson beats Q2 2026 Wall Street estimates and raises full-year guidance as sales top $25B, driven by oncology and MedTech.

Vandana Singh

Earnings Scheduled For July 15, 2026

Companies Reporting Before The Bell • VCI Global (NASDAQ:VCIG) is estimated to report earnings for its Fiscal Year 2025. • PNC Financial Services Gr (NYSE:PNC) is projected to report quarterly earnings at $4.43 per

Benzinga Insights

PRO
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 Est; Raises FY2026 Sales Guidance from $100.300B-$101.300B to $100.800B-$101.400B vs $101.022B Est

Johnson & Johnson (NYSE:JNJ) raises FY2026 Adj EPS guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 analyst estimate. Raises FY2026 sales outlook from $100.300 billion-$101.300 billion to $100.800

Benzinga Newsdesk

PRO
Johnson & Johnson Q2 Adj. EPS $2.90 Beats $2.85 Estimate, Sales $25.310B Beat $25.047B Estimate

]

Benzinga Newsdesk

Johnson & Johnson

Johnson & Johnson Financials

Earnings & Guidance News

Stock Market Today: Dow Jones Futures Gain as Coca-Cola Jumps After Q2 Beat, S&P 500, Nasdaq 100 Decline—Boeing, Johnson & Johnson in Focus (UPDATED)

Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst

Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook

Earnings Scheduled For July 15, 2026

PRO
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 Est; Raises FY2026 Sales Guidance from $100.300B-$101.300B to $100.800B-$101.400B vs $101.022B Est

PRO
Johnson & Johnson Q2 Adj. EPS $2.90 Beats $2.85 Estimate, Sales $25.310B Beat $25.047B Estimate

뉴스

파트너 / 기고자

벤징가 글로벌

Benzinga

Benzinga

Benzinga

Johnson & Johnson

Johnson & Johnson Financials

Earnings & Guidance News

Stock Market Today: Dow Jones Futures Gain as Coca-Cola Jumps After Q2 Beat, S&P 500, Nasdaq 100 Decline—Boeing, Johnson & Johnson in Focus (UPDATED)

Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst

Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook

Earnings Scheduled For July 15, 2026

PROJohnson & Johnson Raises FY2026 Adj EPS Guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 Est; Raises FY2026 Sales Guidance from $100.300B-$101.300B to $100.800B-$101.400B vs $101.022B Est

PROJohnson & Johnson Q2 Adj. EPS $2.90 Beats $2.85 Estimate, Sales $25.310B Beat $25.047B Estimate

Benzinga

뉴스

파트너 / 기고자

벤징가 글로벌

PRO
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 Est; Raises FY2026 Sales Guidance from $100.300B-$101.300B to $100.800B-$101.400B vs $101.022B Est

PRO
Johnson & Johnson Q2 Adj. EPS $2.90 Beats $2.85 Estimate, Sales $25.310B Beat $25.047B Estimate